Inspire Medical Systems Q2 2026 Earnings Beat and Stock Surge

Inspire Medical Systems announced second‑quarter 2026 results that dramatically exceeded Wall Street expectations. The company generated $200.6 million in revenue and posted an adjusted earnings per share of $0.14, turning a consensus forecast of a $0.24 loss per share into a +158.3% earnings surprise. Adjusted EBITDA also outperformed, exceeding analyst estimates by approximately 40%, although the exact EBITDA figure was not disclosed.

Management used the strong quarter to raise its full‑year 2026 revenue outlook to a range of $835 million to $875 million, up from the prior guidance. In addition, the firm unveiled Project Horizon, a strategic restructuring initiative intended to free $30 million of growth capital that will be reinvested directly into market expansion activities.

The earnings release triggered a stock price jump of more than 27% in August, propelling the shares to trade at roughly 34% of their 52‑week high (around a $68 entry price relative to fair‑value models). This move validated an earlier high‑conviction signal from the publisher’s proprietary AI model, which had identified the stock as deeply discounted and fundamentally sound before the results.

Pre‑Earnings AI Model Insights

  • Deep Discount Entry: The AI engine noted the stock was trading at about 34% of its 52‑week high, presenting an asymmetric risk‑reward profile.
  • Accelerating Business Momentum: Prior projections showed full‑year 2025 revenue expanding ~14% to $912 million, with EBITDA increasing over 50%, and Q4 earnings beating expectations by more than 140%.
  • Elite Profitability Profile: The company exhibited an ~85% gross margin and a near‑zero PEG ratio of 0.07, indicating strong profitability despite a low valuation.
  • Reimbursement Tailwinds: A recent CMS reimbursement code update—which had previously sparked a 40% single‑day stock rally—provided clearer coding for the Inspire V device, supporting revenue growth.
  • Clinical Dominance in a $10 billion+ TAM: The Inspire V device’s superior real‑world outcomes continue to capture market share in a largely untapped $10 billion‑plus total addressable market.

Drivers of the Quarter’s Performance

The quarter’s success was attributed to accelerating adoption in Europe, improvements in prior‑authorization workflows, and the clarified reimbursement coding that together boosted sales and profitability. The company’s high gross margin and low PEG ratio underscore its positioning as a high‑margin, growth‑oriented med‑tech business.

Investor Implications

The combination of a blowout earnings beat, raised guidance, and strategic capital allocation via Project Horizon suggests continued upside potential, especially as the company leverages its European momentum and reimbursement advantages. The AI‑driven early identification of the stock’s discount highlights the potential value of quantitative screening tools for high‑conviction, low‑risk entries.